The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.
The calcified plaque-shattering technology developed by Shockwave Medical continues to gain momentum. As more care teams start using IVL during PCI, researchers are paying close attention to its long-term impact on patient care.
Researchers hoped to gain a better understanding of the device's real-world impact by reviewing registry data from more than 97,000 U.S. patients. Overall, the Watchman FLX was linked to positive data and limited adverse events one year after treatment.
Follow-up MRI in patients with mild traumatic brain injuries could help predict if they will experience lingering symptoms months later, even if their initial imaging was normal.
The J Valve from JC Medical was linked to positive outcomes and “excellent” hemodynamic data after 30 days in an early feasibility study published in JACC: Cardiovascular Interventions. Researchers noted that the valve showed potential in patients with large aortic annuli, which represents an "unmet critical need" at this stage.
The study's findings indicate that obtaining a prostate MRI at the time of a patient's initial diagnosis may provide important insight into how cancer will progress over time.
Finerenone, sold under the brand name Kerendia, is already approved by the FDA for reducing heart and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes. Bayer plans on presenting the new data in full at ESC Congress 2024 in London.
![Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S](/sites/default/files/styles/240x220/public/2024-08/screenshot_2024-08-12_at_11.35.13_am.png.webp?itok=YxsSJPAl)
